革命性的抗凝药:纳米工程疗法和精准医学方法
Ying Zhang1, Wenqiang Qian2, Weidong Fei2
1Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China; Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
International journal of pharmaceutics
|April 16, 2025
概括
工程抗凝疗法,包括纳米平台和DNA原形,提供精确的,无药物调节凝固因子. 这些先进的策略有望为血栓性疾病提供更安全,更个性化的治疗方法.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗血栓治疗对于预防和治疗心血管疾病至关重要.
- 目前的抗凝血方法面临着出血和耐药性等挑战.
- 需要新的方法来提高抗凝血剂的有效性和安全性.
研究的目的:
- 审查抗凝固因子装载纳米平台的进展.
- 探索超越传统药物的新型抗凝技术.
- 检查结合生物医学工程的精确抗凝策略.
主要方法:
- 对抗凝固因子装载的纳米平台进行针对性药物输送的审查.
- 对生物相容纳米材料,DNA原形和能量介导抗凝剂的分析.
- 检查针对个体患者条件量身定制的精确抗凝策略.
主要成果:
- 纳米平台可以提高药物的生物可用性,减少系统性副作用.
- 工程系统调节抗凝固因子,而不需要传统药物,以获得个性化的效果.
- 精确策略将治疗量身定制为特定的病理状况,减少过度抗凝血风险.
结论:
- 工程抗凝疗法在治疗血栓性疾病方面取得了重大进展.
- 这些新的策略提供了更精确,更安全的抗凝固解决方案.
- 这些发现为未来的个性化医疗和抗凝治疗中的精密疗法提供了指导.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
546
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
546
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
392
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
392
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Clot Retraction and Fibrinolysis
2.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.8K


